Dr. Raza Hoda discussed findings from the DESTINY-Breast04 and DESTINY-Breast06 trials at the San Antonio Breast Cancer Symposium. The retrospective study evaluated patients with metastatic breast cancer to determine their eligibility for HER2-directed antibody-drug conjugates. The study found no significant differences in clinical and pathologic variations among patients with hormone receptor-positive, HER2-low, HER2-ultralow, and HER2-null metastatic breast cancer. This suggests that patients with these different characteristics may benefit from HER2-directed therapies such as trastuzumab deruxtecan. The results were presented at the conference by Dr. Hoda and his colleague, Dr. Patrick McIntire.
Source link
Study investigates HER2-low, ultralow eligibility for trastuzumab deruxtecan
